US Patent

US11236121 — Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid

Composition of Matter · Assigned to Sage Therapeutics Inc · Expires 2037-08-23 · 11y remaining

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a crystalline form of a 19-nor C3,3-disubstituted C21-pyrazolyl steroid, also known as the active substance in the drug Zurzuvae.

USPTO Abstract

This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US11236121
Jurisdiction
US
Classification
Composition of Matter
Expires
2037-08-23
Drug substance claim
Yes
Drug product claim
No
Assignee
Sage Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.